$TBMC
Trailblazer Merger Corp I Stock $tbmc

$tbmc Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000121390024028037 Filed on March 29, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$110.9K	$543.5K	$0.00
YoY Change
Operating Profit		-$543.5K
YoY Change		13420.8%
Interest Expense	$1.004M	$2.615M
YoY Change
% of Operating Profit
Other Income/Expense, Net	$0.00	$2.408M
YoY Change
Pretax Income	$893.3K	$1.864M	$0.00
YoY Change
Income Tax	$210.3K	$517.0K
% Of Pretax Income	23.54%	27.73%
Net Earnings	$683.0K	$1.347M	$0.00
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share		$0.19
Diluted Earnings Per Share	$0.08	$0.19	$0.00
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding		7.221M shares

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$607.8K	$607.8K	$30.00K
YoY Change	1926.07%	1926.07%	0.0%
Cash & Equivalents	$607.8K		$34.39K
Short-Term Investments
Other Short-Term Assets	$141.9K	$141.9K	$0.00
YoY Change			-100.0%
Inventory
Prepaid Expenses	$141.9K		$2.083K
Receivables
Other Receivables
Total Short-Term Assets	$749.8K	$749.8K	$36.48K
YoY Change	1955.47%	1774.38%	-27.05%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$72.99M	$72.99M
YoY Change
Other Assets	$25.68K	$25.68K	$270.0K
YoY Change	-90.49%	-90.49%
Total Long-Term Assets	$73.02M	$73.02M	$265.4K
YoY Change	27415.78%	27984.83%
TOTAL ASSETS
Total Short-Term Assets	$749.8K	$749.8K	$36.48K
Total Long-Term Assets	$73.02M	$73.02M	$265.4K
Total Assets	$73.77M	$73.77M	$301.9K
YoY Change	24339.15%	24490.1%	503.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$238.8K	$238.8K
YoY Change
Accrued Expenses	$75.00K	$75.00K	$1.290K
YoY Change	5713.95%	25.0%
Deferred Revenue
YoY Change
Short-Term Debt	$321.6K	$321.6K	$230.0K
YoY Change	39.82%	39.82%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$942.3K	$942.3K	$282.0K
YoY Change	234.08%	236.52%	464.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.070M	$2.070M
YoY Change
Total Long-Term Liabilities	$2.070M	$2.070M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$942.3K	$942.3K	$282.0K
Total Long-Term Liabilities	$2.070M	$2.070M	$0.00
Total Liabilities	$3.222M	$3.222M	$282.0K
YoY Change	1042.53%	1050.86%	464.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.677M		-$5.187K
YoY Change	32236.03%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.677M	$70.55M	$19.81K
YoY Change
Total Liabilities & Shareholders Equity	$73.77M	$73.77M	$301.9K
YoY Change	24339.15%	24490.1%	503.71%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income	$683.0K	$1.347M	$0.00
YoY Change
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$64.20K	-$471.5K	$0.00
YoY Change		-2457.64%	-100.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$70.38M
YoY Change
Cash From Investing Activities	$0.00	-$70.38M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-3.500K	$71.42M	0.000
YoY Change		-714349.5%	-100.0%
NET CHANGE
Cash From Operating Activities	-64.20K	-$471.5K	0.000
Cash From Investing Activities	0.000	-$70.38M
Cash From Financing Activities	-3.500K	$71.42M	0.000
Net Change In Cash	-67.70K	$573.4K	0.000
YoY Change		5634.23%	-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$64.20K	-$471.5K	$0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41668
CY2023	dei	Entity Registrant Name EntityRegistrantName	TRAILBLAZER MERGER CORPORATION I
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-3710376
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	510 Madison Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1401
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10022
CY2023	dei	City Area Code CityAreaCode	(212)
CY2023	dei	Local Phone Number LocalPhoneNumber	586-8224
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Public Float EntityPublicFloat	70311000	usd
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	New York
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	607816	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34393	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	141937	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2083	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	749753	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	36476	usd
CY2023Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	25681	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	265377	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	72994863	usd
CY2023Q4	us-gaap	Assets Assets	73770297	usd
CY2022Q4	us-gaap	Assets Assets	301853	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	238834	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1290	usd
CY2023Q4	tbmcu	Accrued Offering Costs Current AccruedOfferingCostsCurrent	75000	usd
CY2022Q4	tbmcu	Accrued Offering Costs Current AccruedOfferingCostsCurrent	55750	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	306834	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	942253	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	282040	usd
CY2023Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	210152	usd
CY2023Q4	tbmcu	Deferred Underwriting Fee Payable Non Current DeferredUnderwritingFeePayableNonCurrent	2070000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3222405	usd
CY2022Q4	us-gaap	Liabilities Liabilities	282040	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	72224950	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	24828	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1677270	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5187	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1677058	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	19813	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73770297	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	301853	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	543536	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	4020	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-543536	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4020	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	207087	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	2606031	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	8832	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2407776	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1864240	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4020	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	516986	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	1347254	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4020	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7220855	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	406849	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1167	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4020	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	19813	usd
CY2023	tbmcu	Stock Issued During Period Value Private Placement Units StockIssuedDuringPeriodValuePrivatePlacementUnits	3945000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	207087	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	745200	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	89233	usd
CY2023	tbmcu	Stock Issued During Period Shares Private Placement Units StockIssuedDuringPeriodSharesPrivatePlacementUnits	394500	shares
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	7852179	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	1347254	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1677058	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	1347254	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4020	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	207087	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	2606031	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	8832	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	210152	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	139854	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-22917	usd
CY2023	us-gaap	Increase Decrease In Prepaid Insurance IncreaseDecreaseInPrepaidInsurance	25681	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	237544	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	123	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	306834	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-471527	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	19020	usd
CY2023	tbmcu	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	70380000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70380000	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	67965000	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3945000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	100000	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	100085	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	100000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3500	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	581635	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	209627	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	71424950	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-9627	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	573423	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	9393	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34393	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	607816	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34393	usd
CY2023	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	75000	usd
CY2022	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	55750	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	25000	usd
CY2023	tbmcu	Accretion Of Common Stock To Redemption Value AccretionOfCommonStockToRedemptionValue	7852179	usd
CY2023	tbmcu	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	2070000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.35pt 0pt 0"><b>NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</b></p> <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trailblazer Merger Corporation I (the “Company”) is a blank check company incorporated in Delaware on November 12, 2021. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses (the “Business Combination”).</p> <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 1.35pt 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is not limited to a particular industry or geographic location for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. While the Company may pursue an initial business combination target in any business or industry, the Company intends to focus the search for a target business on companies operating in the technology industry.</p> <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, the Company had not yet commenced any operations. All activity for the period November 12, 2021 (inception) through December 31, 2023 relates to the Company’s formation and the initial public offering (the “Initial Public Offering”), which is described below. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end.</p> <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registration statement for the Company’s Initial Public Offering was declared effective on March 28, 2023. On March 31, 2023, the Company consummated the Initial Public Offering of 6,900,000 units (the “Units” and, with respect to the shares of Class A common stock included in the Units being offered, the “Public Shares”), which includes the full exercise by the underwriters of their over-allotment option in the amount of 900,000 Units, at $10.00 per Unit, generating gross proceeds of $69,000,000 which is described in Note 3.</p> <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 394,500 units (the “Placement Units”) at a price of $10.00 per Placement Unit, in a private placement to Trailblazer Sponsor Group, LLC (the “Sponsor”), generating gross proceeds of $3,945,000, which is described in Note 4.</p> <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transaction costs amounted to $3,971,262 consisting of $1,035,000 of cash underwriting discount, $2,070,000 of deferred underwriting fees, and $866,262 of other offering costs. The allocated value of transaction costs to Class A common stock amounted to $89,233.</p> <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the closing of the Initial Public Offering on March 31, 2023, an amount of $70,380,000 ($10.20 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Placement Units was placed in a trust account (the “Trust Account”) and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination or (ii) the distribution of the funds in the Trust Account to the Company’s stockholders, as described below.</p> <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on interest earned on the Trust Account) at the time of the signing a definitive agreement to enter a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940. There is no assurance that the Company will be able to successfully effect a Business Combination.</p> <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will provide its holders of the outstanding Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.20 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations).</p> <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company seeks stockholder approval, it will only proceed with a Business Combination, if a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”), which will be filed prior to the Initial Public Offering, increase the number of authorized shares, conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5), placement shares (shares of Class A common stock included in the Placement Units) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or don’t vote at all.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the above, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sponsor has agreed (a) to waive its redemption rights with respect to its Founder Shares and Public Shares held by it in connection with the completion of a Business Combination, (b) to waive its liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within 12 months from the closing of the Initial Public Offering (or up to 18 months, if we extend the time to complete a business combination as described in this prospectus) and (c) not to propose an amendment to the Amended and Restated Certificate of Incorporation (i) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the Company’s initial Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination or with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will have until 12 months from the closing of the Initial Public Offering, or until March 31, 2024, to complete a Business Combination. However, if the Company anticipates that it may not be able to consummate a Business Combination within 12 months, the Company may, by resolution of its Board of Directors and if requested by the Sponsor, extend the period of time the Company has to consummate a Business Combination up to two times, each by an additional three months (for a total of up to 18 months), provided that, pursuant to the terms of the Company’s Amended and Restated Certificate of Incorporation and the trust agreement entered into between the Company and Continental Stock Transfer & Trust Company in connection with the Initial Public Offering, in order for the time available for the Company to consummate a Business Combination to be extended, the Sponsor or its affiliates or designees, upon five days’ advance notice prior to the applicable deadline, must deposit into the trust account $690,000 in full, (or $0.10 per share) for each extension, on or prior to the date of the applicable deadline. If the Company is unable to complete a Business Combination within 12 months (or 18 month period if extended) (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On February 29, 2024, the board of directors approved the exercise by the Company of the automatic extension of the time the Company has to complete a business combination by an additional three months to June 30, 2024 (see Note 10).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On March 28, 2024, the Sponsor deposited $ 690,000 into the Company’s trust account in order to extend the date by which the Company has to consummate a business combination from March 31, 2024 to June 30, 2024 (see Note 10).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sponsor has agreed to waive its liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor acquires Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.20 per Public Share or (2) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay our taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Going Concern Consideration</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $25,000 from the Sponsor issuance of Founder Shares and loan proceeds from the Sponsor under the Promissory Note (as defined in Note 5). Subsequent to the consummation of the Initial Public Offering, the Company’s liquidity has been satisfied through the net proceeds from the Initial Public Offering and the sale of the Placement Units in a private placement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, it would repay such loaned amounts at that time. Up to $1,500,000 of such Working Capital Loans may be converted into units of the post-Business Combination entity at a price of $10.00 per unit at the option of the lender. The units would be identical to the Placement Units. As of December 31, 2023 and 2022, there was no amount outstanding under the Working Capital Loan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Company’s assessment of going concern considerations in accordance with the authoritative guidance in Financial Accounting Standard Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the Company currently lacks the liquidity it needs to sustain operations for a reasonable period of time, which is considered to be at least <span style="-sec-ix-hidden: hidden-fact-74">one</span> year from the date that the financial statements are issued as it expects to continue to incur significant costs in pursuit of its acquisition plans. In addition, the Company has until June 30, 2024 (as extended, or September 30, 2024 if we extend the period of time to consummate a Business Combination by the full amount of time) to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by this time. If a Business Combination is not consummated by June 30, 2024 (or September 30, 2024, if extended by the full amount of time), there will be a mandatory liquidation and subsequent dissolution. Management has determined that mandatory liquidation, should a Business Combination not occur, and an extension not be approved by the stockholders of the Company, and potential subsequent dissolution and the liquidity issue raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date the financial statements are issued. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after June 30, 2024 (or September 30, 2024, if extended by the full amount of time). The Company intends to continue to search for and seek to complete a Business Combination before the mandatory liquidation date. The Company is within 12 months of its mandatory liquidation date as of the time of filing of this Annual Report on Form 10-K.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Inflation Reduction Act of 2022</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its stockholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any redemption or other repurchase that occurs after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any “PIPE” or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and in the Company’s ability to complete a Business Combination.</p>
CY2023Q4	tbmcu	Transaction Costs TransactionCosts	3971262	usd
CY2023	tbmcu	Underwriter Cash Discount UnderwriterCashDiscount	1035000	usd
CY2023	tbmcu	Deferred Underwriting Fees DeferredUnderwritingFees	2070000	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	866262	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	89233	usd
CY2023	tbmcu	Threshold Minimum Aggregate Fair Market Value As Percentage Of Assets Held In Trust Account ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount	0.80	pure
CY2023	tbmcu	Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination	0.50	pure
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.2
CY2023	tbmcu	Threshold Percentage Of Public Shares Subject To Redemption Without Companys Prior Written Consent ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent	0.15	pure
CY2023	tbmcu	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
CY2023	tbmcu	Investment Of Cash Into Trust Account InvestmentOfCashIntoTrustAccount	690000	usd
CY2023	tbmcu	Maximum Net Interest To Pay Dissolution Expenses MaximumNetInterestToPayDissolutionExpenses	100000	usd
CY2022Q3	tbmcu	Percentage Of Excise Tax PercentageOfExciseTax	0.01	pure
CY2023	tbmcu	Percentage Of Excise Tax PercentageOfExciseTax	0.01	pure
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	607816	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34393	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	581635	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	209627	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on this account.</p>
CY2023	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1940624	shares
CY2023Q4	us-gaap	Investment Company Voluntary Payment By Affiliate Loss Reimbursement InvestmentCompanyVoluntaryPaymentByAffiliateLossReimbursement	3545	usd
CY2023	tbmcu	Underwriters Option Period From Date Of Initial Public Offering UnderwritersOptionPeriodFromDateOfInitialPublicOffering	P45Y
CY2023	tbmcu	Underwriter Cash Discount UnderwriterCashDiscount	1035000	usd
CY2023	tbmcu	Underwriters Fees As Percentage Of Total Consideration UnderwritersFeesAsPercentageOfTotalConsideration	0.015	pure
CY2023Q4	us-gaap	Share Price SharePrice	10
CY2023Q4	us-gaap	Provision For Loss On Contracts ProvisionForLossOnContracts	50000	usd
CY2023Q4	us-gaap	Product Liability Contingency Loss Exposure In Excess Of Accrual Best Estimate ProductLiabilityContingencyLossExposureInExcessOfAccrualBestEstimate	50000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	82679	usd
CY2022Q4	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	672	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	210152	usd
CY2023Q4	tbmcu	Deferred Taxliability Asset Net DeferredTaxliabilityAssetNet	127473	usd
CY2022Q4	tbmcu	Deferred Taxliability Asset Net DeferredTaxliabilityAssetNet	-672	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	82679	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	672	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	210152	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	306834	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	128145	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-672	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	82007	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	672	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	516986	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	82007	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	672	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.023	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.044	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.167	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.277	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.043	pure
CY2023Q4	us-gaap	Cash Cash	152	usd
CY2023	tbmcu	Median Market Price Of Right MedianMarketPriceOfRight	0.108
CY2023Q4	us-gaap	Deferred Costs DeferredCosts		usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent		usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent		usd
CY2022Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent		usd
CY2022Q4	tbmcu	Deferred Underwriting Fee Payable Non Current DeferredUnderwritingFeePayableNonCurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Increase Decrease In Prepaid Insurance IncreaseDecreaseInPrepaidInsurance		usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable		usd
CY2022	tbmcu	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2023	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	tbmcu	Accretion Of Common Stock To Redemption Value AccretionOfCommonStockToRedemptionValue		usd
CY2022	tbmcu	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable		usd
CY2023	tbmcu	Financial Statement Term FinancialStatementTerm	P1Y
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued		usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued		usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001934945

Files In Submission

Name	View Source	Status
0001213900-24-028037-index-headers.html	Edgar Link	pending
0001213900-24-028037-index.html	Edgar Link	pending
0001213900-24-028037.txt	Edgar Link	pending
0001213900-24-028037-xbrl.zip	Edgar Link	pending
ea0200788-10k_trail1.htm	Edgar Link	pending
ea020078801ex10-14_trail1.htm	Edgar Link	pending
ea020078801ex21-1_trail1.htm	Edgar Link	pending
ea020078801ex31-1_trail1.htm	Edgar Link	pending
ea020078801ex31-2_trail1.htm	Edgar Link	pending
ea020078801ex32-1_trail1.htm	Edgar Link	pending
ea020078801ex4-5_trail1.htm	Edgar Link	pending
ea020078801ex97-1_trail1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ea0200788-10k_trail1_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tbmcu-20231231.xsd	Edgar Link	pending
tbmcu-20231231_lab.xml	Edgar Link	unprocessable
tbmcu-20231231_pre.xml	Edgar Link	unprocessable
tbmcu-20231231_cal.xml	Edgar Link	unprocessable
tbmcu-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TBMC
Trailblazer Merger Corp I Stock $tbmc

2023 Q4 Form 10-K Financial Statement

#000121390024028037 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TBMC Trailblazer Merger Corp I Stock $tbmc

2023 Q4 Form 10-K Financial Statement

#000121390024028037 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TBMC
Trailblazer Merger Corp I Stock $tbmc